Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life

Movement Disorders

Volumn 21, Issue 8, 2006, Pages 1119-1122

  Antonini, Angelo ^a   Tesei, Silvana ^a   Zecchinelli, Anna ^a   Barone, Paolo ^b   De Gaspari, Danilo ^a   Canesi, Margherita ^a   Sacilotto, Giorgio ^a   Meucci, Nicotta ^a   Mariani, Claudio ^a   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Amitriptyline; Depression; Parkinson's disease; Sertraline

Indexed keywords

AMANTADINE; AMITRIPTYLINE; CABERGOLINE; CITALOPRAM; ENTACAPONE; LEVODOPA; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REGIMEN; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MALE; MOBILIZATION; MOTOR PERFORMANCE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF CONCEPT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STIGMA; TACHYCARDIA; TREATMENT DURATION; VISUAL HALLUCINATION;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SINGLE-BLIND METHOD;

EID: 33748346259     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20895     Document Type: Article

References (17)

1. Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000;320:1287-1288.
2. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-375.
3. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002;17:60-67.
4. Richard IH, Kurlan R, and the Parkinson Study Group A survey of antidepressant drug use in Parkinson's disease. Neurology 1997; 49:1168-1170.
5. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-989.
6. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994, 9(Suppl. 1):19-26.
7. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 1998;12(Suppl. B):S5-S20.
8. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: II. Efficacy and quality of life. Psychopharmacology 1998;12(Suppl. B):S21-S54.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Arlington, VA: American Psychiatric Publishing; 2000.
10. Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003;2:CD003465.
11. Lydiard RB, Stahl SM, Hertzman M, Harrison WM. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Clin Psychiatry 1997;58:484-491.
12. Schneider LS, Nelson JC, Clary CM, et al., for the Setraline Elderly Depression Study Group. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160:1277-1285.
13. Leentjens AF. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17: 120-126.
14. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004;16:315-319.
15. Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology 2005;64:2134-2135.
16. Sakulsripong M, Curran HV, Lader M. Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 1991;40:43-48.
17. Sawabini KA, Watts RL. Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord 2004;(Suppl. 1):S37-S41.